Quick Answer
Passage BIO, Inc. reported Common Stock Shares Outstanding of 3.18 million shares for the year ending 2025.
- Passage BIO, Inc. showed an increase of +0.7% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Passage BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: 45.35 million shares | Q2 2020: 45.44 million shares | Q3 2020: 45.53 million shares | Q1 2021: 53.85 million shares | Q2 2021: 53.96 million shares | Q3 2021: 54.02 million shares | Q1 2022: 54.31 million shares | Q2 2022: 54.46 million shares | Q3 2022: 54.55 million shares | Q1 2023: 54.63 million shares | Q2 2023: 54.75 million shares | Q3 2023: 54.81 million shares | Q1 2024: 61.61 million shares | Q2 2024: 61.75 million shares | Q3 2024: 61.77 million shares | Q1 2025: 62.15 million shares | Q2 2025: 3.18 million shares | Q3 2025: 3.18 million shares.
- Over the full 7 years of available data (2019 to 2025), Passage BIO, Inc.'s Common Stock Shares Outstanding has declined by 25.9%.
- Historical annual values: Fiscal year 2025: 3.18 million shares | Fiscal year 2024: 3.16 million shares | Fiscal year 2023: 54.94 million shares | Fiscal year 2022: 54.61 million shares | Fiscal year 2021: 54.24 million shares | Fiscal year 2020: 45.61 million shares | Fiscal year 2019: 4.29 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: